1450 related articles for article (PubMed ID: 17135584)
21. Pioglitazone in nonalcoholic steatohepatitis.
Targher G
N Engl J Med; 2007 Mar; 356(10):1067; author reply 1068-9. PubMed ID: 17347462
[No Abstract] [Full Text] [Related]
22. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
[TBL] [Abstract][Full Text] [Related]
23. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
24. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
25. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
26. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
27. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Bajaj M; Suraamornkul S; Pratipanawatr T; Hardies LJ; Pratipanawatr W; Glass L; Cersosimo E; Miyazaki Y; DeFronzo RA
Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
Boettcher E; Csako G; Pucino F; Wesley R; Loomba R
Aliment Pharmacol Ther; 2012 Jan; 35(1):66-75. PubMed ID: 22050199
[TBL] [Abstract][Full Text] [Related]
30. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
31. Pioglitazone in the treatment of NASH: the role of adiponectin.
Gastaldelli A; Harrison S; Belfort-Aguiar R; Hardies J; Balas B; Schenker S; Cusi K
Aliment Pharmacol Ther; 2010 Sep; 32(6):769-75. PubMed ID: 20662773
[TBL] [Abstract][Full Text] [Related]
32. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
33. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Ratziu V; Charlotte F; Bernhardt C; Giral P; Halbron M; Lenaour G; Hartmann-Heurtier A; Bruckert E; Poynard T;
Hepatology; 2010 Feb; 51(2):445-53. PubMed ID: 19877169
[TBL] [Abstract][Full Text] [Related]
35. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Hecht J; Tio F; Cusi K
J Clin Endocrinol Metab; 2017 Aug; 102(8):2950-2961. PubMed ID: 28575232
[TBL] [Abstract][Full Text] [Related]
36. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
37. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
Sanyal AJ; Abdelmalek MF; Suzuki A; Cummings OW; Chojkier M;
Gastroenterology; 2014 Aug; 147(2):377-84.e1. PubMed ID: 24818764
[TBL] [Abstract][Full Text] [Related]
38. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
39. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.
Espinoza SE; Wang CP; Tripathy D; Clement SC; Schwenke DC; Banerji MA; Bray GA; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Stentz FB; Reaven PD; DeFronzo RA; Musi N
Age (Dordr); 2016 Dec; 38(5-6):485-493. PubMed ID: 27585671
[TBL] [Abstract][Full Text] [Related]
40. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]